Community-acquired pneumonia
ICD-10 J18.9 · ICD-11 CA40.Z

Treatment of CAP in Hospitalised Adults with MRSA Risk Factors: Prior MRSA Isolation or Recent Parenteral Antibiotic Exposure

Clinical Scenario

This protocol targets adults (age 18 or older) admitted to hospital with community-acquired pneumonia who carry locally validated risk factors for MRSA. Two specific risk factors define this high-risk subgroup:

Prior respiratory isolation of MRSA Previous microbiological evidence of MRSA recovered from respiratory specimens.
Recent hospitalisation with parenteral antibiotic exposure (within 90 days) A strongly validated independent risk factor for MRSA pneumonia.
Why These Risk Factors Matter

Empiric MRSA coverage is not indicated for all hospitalised CAP patients — only those with locally validated risk factors. Prior isolation of MRSA from the respiratory tract and recent hospitalisation with parenteral antibiotic use are among the most consistently supported individual predictors, and are the basis for selecting this treatment pathway.

Treatment Approach

When these risk factors are confirmed, the standard CAP regimen is augmented with empiric anti-MRSA coverage. Microbiological sampling is obtained concurrently to support de-escalation or to confirm ongoing need for targeted therapy. A defined duration of treatment applies for suspected or confirmed MRSA pneumonia.

The complete regimen — including agent selection, de-escalation criteria, and duration — is detailed in the full structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1164/rccm.201908-1581ST

We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present (strong recommendation, moderate quality of evidence).

The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral antibiotics.

Empiric treatment options for MRSA include vancomycin (15 mg/kg every 12 h, adjust based on levels) or linezolid (600 mg every 12 h).

We believe that the duration of therapy for CAP due to suspected or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines.

View source ↗